Zidovudine plus interferon alfa-2b treatment in patients with HIV and chronic active viral hepatitis. 1993

G Visco, and L Alba, and S Grisetti, and P Guarascio, and P Narciso, and P Sette, and C Struglia, and G Tossini, and V Tozzi
L. Spallanzani Hospital for Infectious Diseases, Rome, Italy.

Results are reported for a small study of 11 patients positive for HIV and with chronic active viral hepatitis. Low dose zidovudine/interferon alfa-2b combined treatment produced a general reduction in alanine aminotransferase activities and increased the CD4 lymphocyte count, hepatitis B e seroconversion, and the loss of HIV p24 antigen. The treatment was well tolerated and progression of HIV disease was not seen.

UI MeSH Term Description Entries
D008297 Male Males
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006521 Hepatitis, Chronic INFLAMMATION of the LIVER with ongoing hepatocellular injury for 6 months or more, characterized by NECROSIS of HEPATOCYTES and inflammatory cell (LEUKOCYTES) infiltration. Chronic hepatitis can be caused by viruses, medications, autoimmune diseases, and other unknown factors. Chronic Hepatitis,Cryptogenic Chronic Hepatitis,Hepatitis, Chronic, Cryptogenic,Hepatitis, Chronic Active,Hepatitis, Chronic Persistent,Chronic Active Hepatitis,Chronic Hepatitis, Cryptogenic,Chronic Persistent Hepatitides,Chronic Persistent Hepatitis,Hepatitis, Cryptogenic Chronic
D006526 Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown. Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted,Parenterally-Transmitted Non-A, Non-B Hepatitis,PT-NANBH,Parenterally Transmitted Non A, Non B Hepatitis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077190 Interferon alpha-2 Alpha interferon encoded by the human IFNA2 gene. Recombinant forms are used in the treatment of CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; KAPOSI SARCOMA; MELANOMA; and HAIRY CELL LEUKEMIA. IFN-alpha 2,IFN-alpha-2,IFNalpha-2b, Recombinant,Interferon alfa-2a,Interferon alfa-2b,Interferon alpha-2b, Recombinant,Interferon alpha-A,Interferon-alpha 2,Intron A (Interferon),LeIF A,Reaferon,Recombinant Interferon alpha-2a,Recombinant Interferon alpha-2b,Ro 22-8181,Roferon-A,Sch-30500,Viferon,IFNalpha 2b, Recombinant,Interferon alfa 2a,Interferon alfa 2b,Interferon alpha 2,Interferon alpha 2b, Recombinant,Interferon alpha A,Interferon alpha-2a, Recombinant,Recombinant IFNalpha-2b,Recombinant Interferon alpha 2a,Recombinant Interferon alpha 2b,Ro 22 8181,Ro 228181,Roferon A,RoferonA,Sch 30500,Sch30500

Related Publications

G Visco, and L Alba, and S Grisetti, and P Guarascio, and P Narciso, and P Sette, and C Struglia, and G Tossini, and V Tozzi
December 2004, JAMA,
G Visco, and L Alba, and S Grisetti, and P Guarascio, and P Narciso, and P Sette, and C Struglia, and G Tossini, and V Tozzi
September 2004, AIDS (London, England),
G Visco, and L Alba, and S Grisetti, and P Guarascio, and P Narciso, and P Sette, and C Struglia, and G Tossini, and V Tozzi
July 2014, World journal of hepatology,
G Visco, and L Alba, and S Grisetti, and P Guarascio, and P Narciso, and P Sette, and C Struglia, and G Tossini, and V Tozzi
September 2001, Lancet (London, England),
G Visco, and L Alba, and S Grisetti, and P Guarascio, and P Narciso, and P Sette, and C Struglia, and G Tossini, and V Tozzi
January 1990, Journal of hepatology,
G Visco, and L Alba, and S Grisetti, and P Guarascio, and P Narciso, and P Sette, and C Struglia, and G Tossini, and V Tozzi
June 2001, Clinical pharmacology and therapeutics,
G Visco, and L Alba, and S Grisetti, and P Guarascio, and P Narciso, and P Sette, and C Struglia, and G Tossini, and V Tozzi
January 1999, Seminars in liver disease,
G Visco, and L Alba, and S Grisetti, and P Guarascio, and P Narciso, and P Sette, and C Struglia, and G Tossini, and V Tozzi
August 2007, Antimicrobial agents and chemotherapy,
G Visco, and L Alba, and S Grisetti, and P Guarascio, and P Narciso, and P Sette, and C Struglia, and G Tossini, and V Tozzi
October 1996, American family physician,
G Visco, and L Alba, and S Grisetti, and P Guarascio, and P Narciso, and P Sette, and C Struglia, and G Tossini, and V Tozzi
January 1993, Gut,
Copied contents to your clipboard!